FIELD: chemistry.
SUBSTANCE: invention relates to biotechnology, specifically to obtaining PEGylated interferon alpha (IFN-alpha), and can be used in medicine. A conjugate of IFN-alpha with monomethoxypolyethylene glycol, bonded to N-terminal IFN-cysteine alpha of general formula , is obtained, where: n is a whole number from 454 to 1000; m is a whole number ≥4; NαH-IFN is interferon-α-2b, having interferon alpha activity.
EFFECT: obtained conjugate has IFN-alpha activity and prolonged biological action, which enables its use in pharmaceutical compositions and as a medicinal agent for preventing or treating viral and oncological diseases and diseases accompanied by primary or secondary immunodeficiency states.
23 cl, 9 dwg, 6 tbl, 20 ex
Title | Year | Author | Number |
---|---|---|---|
PEG-MODIFIED HUMAN INTERFERON β-1a MOLECULE WITH ANTIVIRAL, IMMUNOMODULATORY AND ANTIPROLIFERATIVE ACTIVITY, WITH IMPROVED STABILITY, REDUCED IMMUNOGENICITY, IMPROVED PHARMACOKINETIC AND PHARMACODYNAMIC PARAMETERS, SUITABLE FOR MEDICAL USE, AND IMMUNOBIOLOGICAL FORMULATION BASED THEREON | 2013 |
|
RU2576372C2 |
NEW FUNCTIONAL, HIGH-PURITY STABLE CONJUGATE OF GRANULOCYTE COLONY-STIMULATING FACTOR (G-CSF) AND POLYETHYLENE GLYCOL WITH PROLONGED BIOLOGICAL ACTION, APPLICABLE FOR MEDICAL PURPOSES, AND BASED IMMUNOBIOLOGICAL AGENT | 2010 |
|
RU2446173C1 |
PEG DENDRIMER WITH FOUR BRANCHES FOR CONJUGATION WITH PROTEINS AND PEPTIDES | 2006 |
|
RU2409389C2 |
NEW FORMULATION CONTAINING POLYETHYLENE GLYCOL (PEG) CONJUGATED INTERFERON ALPHA-2BETA CHARACTERISED BY LESS PAINFUL ADMINISTRATION | 2014 |
|
RU2572800C1 |
EXTENDED FACTOR OF HUMAN ERYTHROPOIESIS AND A THERAPEUTIC AGENT BASED THEREON | 2015 |
|
RU2664588C2 |
CONJUGATES OF PROTEIN AND POLYETHYLENE GLYCOL DERIVATIVE, PHARMACEUTICAL COMPOSITION, METHOD FOR CONTROL OF VIRAL INFECTION | 2004 |
|
RU2298560C2 |
POLYETHYLENE GLYCOL MODIFIED INTERFERON ALPHA 2B, PRODUCING AND USING PREPARATION | 2007 |
|
RU2485134C2 |
PHARMACEUTICAL COMPOSITION AND A METHOD OF TREATMENT OF GROWTH HORMONE-RELATED DISEASES IN HUMANS | 2019 |
|
RU2802215C2 |
PHARMACEUTICAL COMPOSITION AND METHOD OF TREATING GROWTH HORMONE-ASSOCIATED DISEASES IN HUMANS | 2014 |
|
RU2689336C2 |
MEDICINAL AGENT BASED ON MODIFIED ALPHA INTERFERON WITH PROLONGED THERAPEUTIC ACTION | 2008 |
|
RU2382048C1 |
Authors
Dates
2012-04-10—Published
2010-07-20—Filed